AIDS-related Kaposi's sarcoma can occur during peginterferon-α and ribavirin therapy for chronic hepatitis C infection

0Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Introduction: Before the arrival of highly active antiretroviral therapy (HAART), interferon α has been used successfully to treat AIDS-related Kaposi's sarcoma (KS). Peginterferon-α (pegIFN-α) may still be used successfully in refractory KS. Case: Peginterferon-α and ribavirin (RBV) were initiated to treat hepatitis C virus (HCV) infection in an HIV-infected patient with high CD4 counts having discontinued antiretroviral therapy (ART). He developed disseminated KS 6 months after HCV treatment began. Beginning of ART, discontinuation of pegIFN/RBV, and 2 cycles of doxorubicine were necessary to treat KS. Discussion: Despite its activity on KS, thanks to its antiviral and antiangiogenic properties, PegIFN was unable to prevent the occurrence of severe KS. The absence of ART, despite high CD4 counts, and interferon-induced lymphopenia probably triggered the occurrence of KS in this patient. © SAGE Publications 2012.

Cite

CITATION STYLE

APA

De Lastours, V., Pavie, J., Delaugerre, C., & Molina, J. M. (2012). AIDS-related Kaposi’s sarcoma can occur during peginterferon-α and ribavirin therapy for chronic hepatitis C infection. Journal of the International Association of Physicians in AIDS Care, 11(1), 9–11. https://doi.org/10.1177/1545109711420875

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free